海外の治験の状況「1」での検索結果
251件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 地域
- 登録日
Authorised
- Empagliflozin as Adjunctive to inSulin thErapy in Type 1 diabetes over 52 weeks (EASE-2)
- Type 1 diabetes mellitus br>MedDRA version: 19.1 Level: PT Classification code 10067584 Term: Type 1 diabetes mellitus System Organ Class: 10027433 - Metabolism and nutrition disorders ;Therapeutic area: Body processes [G] - Metabolic Phenomena [G03]
- Australia, Austria, Belgium, Canada, Czech Republic, Denmark, Finland, France, Germany, Netherlands, Norway, Poland, Spain, Sweden, Taiwan, United Kingdom, United States
- 2015-04-02
Authorised
- A Phase II Study of 1-(2-chloroethyl)-1-nitroso-3-(2-hydroxyethyl)-urea (HECNU) in pancreatic cancer - Phase II trial with FFC33
- Pancreatic cancer
- Austria
- 2005-07-20
Authorised
- A prospective, multicentre, open-label, centrally allocated, active-controlled, phase 2 study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line
- Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third line br>MedDRA version: 17.1 Level: PT Classification code 10033158 Term: Ovarian epithelial cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Czech Republic, France, Germany, Italy, Spain, United Kingdom, United States
- 2014-02-07
Authorised
- Study to evaluate the efficacy and safety of masitinib in combination with gemcitabine versus gemcitabine alone in advanced / metastatic epithelial ovarian cancer patients in second line being refractory to first line platinum treatment or in third line.
- Advanced/metastatic epithelial ovarian cancer in second line being refractory to first line platinum treatment or in third line br>MedDRA version: 16.1 Level: PT Classification code 10033158 Term: Ovarian epithelial cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Austria, Belgium, Czech Republic, France, Germany, Italy, Spain, United Kingdom, United States
- 2014-02-07
Authorised
- A trial investigating the feasibility of determining the liver glucose production during induced hypoglycaemic in type 1 diabetes mellitus subjects
- Diabetes Mellitus Type 1;Therapeutic area: Diseases [C] - Hormonal diseases [C19]
- Austria
- 2013-11-21
Authorised
- A randomised, double-blind, placebo-controlled Phase II study to target the type I IFN receptor by administrating Anifrolumab in patients with rheumatoid arthritis who have a high interferon signature (TarIFNiRA)
- High IFN siganture in patients with rheumatoid arthritis MedDRA version: 20.0 Level: PT Classification code 10039073 Term: Rheumatoid arthritis System Organ Class: 10028395 - Musculoskeletal and connective tissue disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Austria, Italy, Switzerland
- 2017-08-17
Authorised
- Effect of insulin glulisine compared to insulin aspart and insulin lispro when administered by Continuous Subcutaneous Insulin Infusion (CSII) on specific pump parameters in patient with Type 1 Diabetes Mellitus - Pump Study
- Type I Diabetes Mellitus MedDRA version: 9.1 Level: LLT Classification code 10045228 Term: Type I diabetes mellitus
- Austria, France, Hungary, Italy, Netherlands, Spain, Sweden, United Kingdom
- 2007-10-04
Authorised
- A prospective, multicenter, randomized, open-label, active-controlled, 2-parallel group, phase III study to compare efficacy and safety of masitinib at 7.5 mg/kg/day to imatinib at 400 or 600 mg in treatment of patients with gastro-intestinal stromal tumour in first line medical treatment
- gastro-intestinal stromal tumour MedDRA version: 9.1 Level: LLT Classification code 10051066 Term: Gastrointestinal stromal tumour
- Austria, Belgium, France, Germany, Hungary, Netherlands, Spain, United Kingdom
- 2008-07-16
Authorised
- Clinical Trial Testing the Safety of Four Ramucirumab Doses Given as Second Line Treatment to Patients with Stomach Cancer
- Second Line Gastric or Gastroesophageal Junction Adenocarcinoma MedDRA version: 18.0 Level: PT Classification code 10063916 Term: Metastatic gastric cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, France, Hungary, New Zealand, Poland, Romania, Russian Federation, Slovakia, United Kingdom, United States
- 2015-03-04
Authorised
- A study evaluating safety and efficacy of Itacitinib or Placebo in combination with corticosteroids for the treatment of first-line acute graft versus-host disease
- Male or female, 18 years of age or older who have received an allogeneic hematopoietic stem cell transplant (allo-HSCT) and have developed Grade II to IV acute GVHD MedDRA version: 20.1 Level: PT Classification code 10066260 Term: Acute graft versus host disease System Organ Class: 10021428 - Immune system disorders MedDRA version: 20.1 Level: PT Classification code 10066262 Term: Acute graft versus host disease in skin System Organ Class: 10021428 - Immune system disorders MedDRA version: 20.1 Level: PT Classification code 10066264 Term: Acute graft versus host disease in intestine System Organ Class: 10021428 - Immune system disorders MedDRA version: 20.1 Level: PT Classification code 10066263 Term: Acute graft versus host disease in liver System Organ Class: 10021428 - Immune system disorders ;Therapeutic area: Diseases [C] - Immune System Diseases [C20]
- Australia, Austria, Belgium, Canada, Czech Republic, Finland, Greece, Hungary, Israel, Korea, Republic of, Netherlands, New Zealand, Portugal, Singapore, Spain, Switzerland, Taiwan, Turkey, United States
- 2017-07-20